{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:56:01Z","timestamp":1790776561682,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["1U01CA215547"],"award-info":[{"award-number":["1U01CA215547"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","award":["BCRF"],"award-info":[{"award-number":["BCRF"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Our objective was to assess whether modifications to a customized targeted RNA sequencing (RNAseq) assay to include unique molecular identifiers (UMIs) that collapse read counts to their source mRNA counts would improve quantification of transcripts from formalin-fixed paraffin-embedded (FFPE) tumor tissue samples. The assay (SET4) includes signatures that measure hormone receptor and PI3-kinase related transcriptional activity (SET<jats:sub>ER\/PR<\/jats:sub> and PI3Kges), and measures expression of selected activating point mutations and key breast cancer genes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Modifications included steps to introduce eight nucleotides-long UMIs during reverse transcription (RT) in bulk solution, followed by polymerase chain reaction (PCR) of labeled cDNA in droplets, with optimization of the polymerase enzyme and reaction conditions. We used Lin\u2019s concordance correlation coefficient (CCC) to measure concordance, including precision (Rho) and accuracy (Bias), and nonparametric tests (Wilcoxon, Levene\u2019s) to compare the modified (NEW) SET4 assay to the original (OLD) SET4 assay and to whole transcriptome RNAseq using RNA from matched fresh frozen (FF) and FFPE samples from 12 primary breast cancers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The modified (NEW) SET4 assay measured single transcripts (<jats:italic>p<\/jats:italic>&lt;\u20090.001) and SET<jats:sub>ER\/PR<\/jats:sub> (<jats:italic>p<\/jats:italic>=0.002) more reproducibly in technical replicates from FFPE samples. The modified SET4 assay was more precise for measuring single transcripts (Rho 0.966 vs 0.888, <jats:italic>p<\/jats:italic>&lt;\u20090.01) but not multigene expression signatures SET<jats:sub>ER\/PR<\/jats:sub> (Rho 0.985 vs 0.968) or PI3Kges (Rho 0.985 vs 0.946) in FFPE, compared to FF samples. It was also more precise than wtRNAseq of FFPE for measuring transcripts (Rho 0.986 vs 0.934, <jats:italic>p<\/jats:italic>&lt;\u20090.001) and SET<jats:sub>ER\/PR<\/jats:sub> (Rho 0.993 vs 0.915, <jats:italic>p<\/jats:italic>=0.004), but not PI3Kges (Rho 0.988 vs 0.945, <jats:italic>p<\/jats:italic>=0.051). Accuracy (Bias) was comparable between protocols. Two samples carried a <jats:italic>PIK3CA<\/jats:italic> mutation, and measurements of transcribed mutant allele fraction was similar in FF and FFPE samples and appeared more precise with the modified SET4 assay. Amplification efficiency (reads per UMI) was consistent in FF and FFPE samples, and close to the theoretically expected value, when the library size exceeded 400,000 aligned reads.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Modifications to the targeted RNAseq protocol for SET4 assay significantly increased the precision of UMI-based and reads-based measurements of individual transcripts, multi-gene signatures, and mutant transcript fraction, particularly with FFPE samples.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-07814-8","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T12:06:13Z","timestamp":1612440373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples"],"prefix":"10.1186","volume":"21","author":[{"given":"Chunxiao","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Marczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Trevarton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno V.","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah E.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Hatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-184X","authenticated-orcid":false,"given":"W. Fraser","family":"Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"7814_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ymeth.2017.06.032","volume":"131","author":"S Lal","year":"2017","unstructured":"Lal S, McCart Reed AE, de Luca XM, Simpson PT. Molecular signatures in breast cancer. Methods. 2017;131:135\u201346.","journal-title":"Methods"},{"issue":"5","key":"7814_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/nrg.2016.10","volume":"17","author":"SA Byron","year":"2016","unstructured":"Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016;17(5):257\u201371.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"7814_CR3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/1471-2164-15-1008","volume":"15","author":"D Fumagalli","year":"2014","unstructured":"Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Roth\u00e9 F, Majjaj S, Salgado R, Larsimont D, et al. Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-sequencing technology. BMC Genomics. 2014;15(1):1008.","journal-title":"BMC Genomics"},{"key":"7814_CR4","first-page":"1","volume":"2","author":"J Li","year":"2018","unstructured":"Li J, Fu C, Speed TP, Wang W, Symmans WF. Accurate RNA sequencing from formalin-fixed Cancer tissue to represent high-quality Transcriptome from frozen tissue. JCO Precision Oncol. 2018;2:1\u20139.","journal-title":"JCO Precision Oncol"},{"issue":"1","key":"7814_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1186\/s12885-019-6363-0","volume":"19","author":"M Marczyk","year":"2019","unstructured":"Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Sinn BV, Gould RE, Pusztai L, Hatzis C, Symmans WF. The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues. BMC Cancer. 2019;19(1):1189.","journal-title":"BMC Cancer"},{"issue":"1","key":"7814_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-019-0111-0","volume":"5","author":"BV Sinn","year":"2019","unstructured":"Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Murthy R, et al. SETER\/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer. 2019;5(1):16.","journal-title":"NPJ Breast Cancer"},{"issue":"20","key":"7814_CR7","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast Cancer. N Engl J Med. 2019;380(20):1929\u201340.","journal-title":"N Engl J Med"},{"issue":"10","key":"7814_CR8","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2018.1778","volume":"4","author":"SJ Luen","year":"2018","unstructured":"Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi OM, Demanse D, JeBailey L, Dolan S, et al. Association of Somatic Driver Alterations with Prognosis in postmenopausal, hormone receptor-positive, HER2-negative early breast Cancer: a secondary analysis of the BIG 1-98 randomized clinical trial. JAMA Oncol. 2018;4(10):1335\u201343.","journal-title":"JAMA Oncol"},{"issue":"22","key":"7814_CR9","doi-asserted-by":"publisher","first-page":"10208","DOI":"10.1073\/pnas.0907011107","volume":"107","author":"S Loi","year":"2010","unstructured":"Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A. 2010;107(22):10208\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7814_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nbt.2024","volume":"30","author":"TR Mercer","year":"2011","unstructured":"Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Trapnell C, Jeddeloh JA, Mattick JS, Rinn JL. Targeted RNA sequencing reveals the deep complexity of the human transcriptome. Nat Biotechnol. 2011;30(1):99\u2013104.","journal-title":"Nat Biotechnol"},{"key":"7814_CR11","doi-asserted-by":"crossref","unstructured":"Martin DP, Miya J, Reeser JW, Roychowdhury S. Targeted RNA sequencing assay to characterize gene expression and genomic alterations. J Vis Exp. 2016;114:1-9.","DOI":"10.3791\/54090"},{"issue":"24","key":"7814_CR12","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/jnci\/djr438","volume":"103","author":"C Hatzis","year":"2011","unstructured":"Hatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst. 2011;103(24):1871\u201383.","journal-title":"J Natl Cancer Inst"},{"issue":"Web Server issu","key":"7814_CR13","doi-asserted-by":"publisher","first-page":"W5","DOI":"10.1093\/nar\/gkn201","volume":"36","author":"M Johnson","year":"2008","unstructured":"Johnson M, Zaretskaya I, Raytselis Y, Merezhuk Y, McGinnis S, Madden TL. NCBI BLAST: a better web interface. Nucleic Acids Res. 2008;36(Web Server issue):W5\u20139.","journal-title":"Nucleic Acids Res"},{"key":"7814_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2307\/2532051","volume":"45","author":"L Lin","year":"1989","unstructured":"Lin L. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255\u201368.","journal-title":"Biometrics"},{"issue":"10","key":"7814_CR15","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11(10):R106.","journal-title":"Genome Biol"},{"key":"7814_CR16","unstructured":"ThermoFisher Scientific Inc.: SuperScript IV Reverse Transcriptase\u2014 top IV reasons to love the best Super RT yet. In.; 2015: https:\/\/www.thermofisher.com\/content\/dam\/LifeTech\/global\/life-sciences\/PCR\/pdfs\/1015\/SuperScript-IV-Flyer.pdf."},{"issue":"1","key":"7814_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/s12864-018-4933-1","volume":"19","author":"Y Fu","year":"2018","unstructured":"Fu Y, Wu P-H, Beane T, Zamore PD, Weng Z. Elimination of PCR duplicates in RNA-seq and small RNA-seq using unique molecular identifiers. BMC Genomics. 2018;19(1):531.","journal-title":"BMC Genomics"},{"key":"7814_CR18","unstructured":"Illumina Inc.: Considerations for RNA-Seq read length and coverage. In.; 2020: https:\/\/support.illumina.com\/bulletins\/2017\/2004\/considerations-for-rna-seq-read-length-and-coverage-.html."},{"key":"7814_CR19","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nbt.2957","volume":"32","author":"SM-I Consortium","year":"2014","unstructured":"Consortium SM-I, Su Z, \u0141abaj PP, Li S, Thierry-Mieg J, Thierry-Mieg D, Shi W, Wang C, Schroth GP, Setterquist RA, et al. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the sequencing quality control Consortium. Nat Biotechnol. 2014;32:903.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"7814_CR20","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nbt.2972","volume":"32","author":"S Li","year":"2014","unstructured":"Li S, Tighe SW, Nicolet CM, Grove D, Levy S, Farmerie W, Viale A, Wright C, Schweitzer PA, Gao Y, et al. Multi-platform assessment of transcriptome profiling using RNA-seq in the ABRF next-generation sequencing study. Nat Biotechnol. 2014;32(9):915\u201325.","journal-title":"Nat Biotechnol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07814-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-07814-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07814-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T12:15:01Z","timestamp":1612440901000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-07814-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7814"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-07814-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"5 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involved human subjects research and was carried out in compliance with the Helsinki Declaration with review and oversight from the Institutional Review Board of MD Anderson Cancer Center (protocol LAB08\u20130824). The need for informed consent from human subjects specifically for the use of their samples for this research was waived by based on the new and revised Exemption categories (45CFR 46.104), meeting Exemption Category 4(ii): Information, which may include information about biospecimens, is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify subjects. Institutional Review Board of MD Anderson Cancer Center approved the waiver of consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Disclosures related to this study: WFS, BVS, CH, CF and RL are co-inventors on patent WO2017189976A1 \u201cTargeted measure of transcriptional activity related to hormone receptors\u201d. WFS, CF and RL own shares of Delphi Diagnostics, without employment or administrative position. Disclosures unrelated to this study: WFS owns shares of IONIS Pharmaceuticals. TP is a paid consultant and owns shares in Delphi Diagnostics. CH is currently an employee of Bristol-Myers Squibb. LP has received consulting fees and honoraria from Astra Zeneca, Merck, Novartis, Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Almac, Biotheranostics and Syndax.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}